Weight evolution in girls treated for idiopathic central precocious puberty with GnRH analogues

Journal of Pediatric Endocrinology and Metabolism

Volumn 19, Issue 11, 2006, Pages 1327-1334

  Aguiar, A L ^a   Couto Silva, A C ^b   Vicente, E J ^b   Freitas, I C ^a   Cruz, T ^a   Adan, Luís F ^a,b,c  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b State of Bahia Center for Diabetes and Endocrinology CEDEBA   (Brazil)

^c NONE   (Brazil)

Author keywords

Girls; GnRH analogue; Precocious puberty; Weight gain

Indexed keywords

GONADORELIN DERIVATIVE; GOSERELIN; LEUPRORELIN;

ANTHROPOMETRY; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; BONE AGE; CHILD; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; OBESITY; PRECOCIOUS PUBERTY; RETROSPECTIVE STUDY;

EID: 33845717001     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2006.19.11.1327     Document Type: Article

References (28)

1. Breyer P, Haider A, Pescovitz OH. Gonadotropin-releasing hormone agonists in the treatment of girls with central precocious puberty. Clin Obstet Gynecol 1993; 36: 764-772.
2. Lahlou N, Carel JC, Chaussain JL, Roger M. Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab 2000; 13: 723-737.
3. Partsch CJ, Sippell WG. Pathogenesis and epidemiology of precocious puberty. Effects of exogenous oestrogens. Hum Reprod Update 2001; 7: 292-302.
4. Kappy MS, Ganong CS. Advances in the treatment of precocious puberty. Adv Pediatr 1994; 41: 223-261.
5. Lee PA. Central precocious puberty. An overview of diagnosis, treatment, and outcome. Endocrinol Metab Clin North Am 1999; 28: 901-918.
6. Plosker GL, Brogden RN. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. Drugs 1994; 48: 930-967.
7. Sippell WG. Diagnosis and treatment of central precocious puberty - can final height be improved? Horm Res 1994; 41: 14-15.
8. Grumbach MM, Styne DM. Puberty: ontogeny, neuroendocrinology, physiology, and disorders. In: Williams RH, Foster DW, Kroenenberg H, Larsen PR, Zorab R, eds. Williams Textbook of Endocrinology, 9th Ed. Philadelphia, PA: W.B. Saunders, 1998; 1509-1625.
9. Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J, Chaussain JL; French Study Group of Decapeptyl in Precocious Puberty. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. J Clin Endocrinol Metab 1999; 84: 1973-1978.
10. Mul D, de Muinck Keizer-Schrama SM, Oostdijk W, Drop SL. Auxological and biochemical evaluation of pubertal suppression with the GnRH agonist leuprolide acetate in early and precocious puberty. Horm Res 1999; 51: 270-276.
11. Feuillan PP, Jones JV, Barnes K, Oerter-Klein K, Cutler GB Jr. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. J Clin Endocrinol Metab 1999; 84: 44-49.
12. Lebrethon MC, Bourguignon JP. Management of central isosexual precocity: diagnosis, treatment, outcome. Curr Opin Pediatr 2000; 12: 394-399.
13. Arrigo T, De Luca F, Antoniazzi F, Galluzzi F, Segni M, Rosano M, Messina MF, Lombardo F. Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty. Eur J Endocrinol 2004; 150: 533-537.
14. Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of the Hand and Wrist, 2nd Ed. Stanford, CA: Stanford University Press, 1959.
15. Rolland-Cachera MF, Cole TJ, Sempe M, Tichet J, Rossignol C, Charraud A. Body mass index variations: centiles from birth to 87 years. Eur J Clin Nutr 1991; 45: 13-21.
16. Sempe M, Pedron G, Roy-Pernot MP. Auxologie, Méthode et Séquences. Paris: Théraplix, 1979.
17. Heger S, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab 1999; 84: 4583-4590.
18. Midyett K, Moore WV, Jacobson J. Are pubertal changes in girls before age 8 benign? Pediatrics 2003; 111: 47-51.
19. Frisch RE, Reville R. Height and weight at menarche and a hypothesis of critical body weights and adolescent events. Science 1970; 169: 397-399.
20. Garcia-Mayor RV, Andrade MA, Rios M, Lage M, Dieguez C, Casanueva FF. Serum leptin levels in normal children: relationship to age, gender, body mass index, pituitary-gonadal hormones, and pubertal stage I. J Clin Endocrinol Metab 1997; 82: 2849-2855.
21. Ahmed ML, Ong KL, Morrell DJ, Cox L, Drayer N, Perry L, Preece MA, Dunger DB. Longitudinal study of leptin concentrations during puberty: sex differences and relationship to changes in body composition. J Clin Endocrinol Metab 1999; 84: 899-905.
22. Palmert MR, Mansfield MJ, Crowley WF Jr, Crigler JF Jr, Crawford JD, Boepple PA. Is obesity an outcome of gonadotropin-releasing agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab 1999; 84: 4480-4488.
23. Kaplowitz PB, Oberfield SE; Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Pediatrics 1999; 104: 936-941.
24. De Ridder CM, Thijssen JH, Bruning PF, Van den Brande JL, Zonderland ML, Erich WB. Body fat mass, body fat distribution, and pubertal development: a longitudinal study of physical and hormonal sexual maturation of girls. J Clin Endocrinol Metab 1992; 75: 442-446.
25. Boot AM, de Muinck Keizer-Schrama SMPF, Pols HAP, Krenning EP, Prop SLS. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty. J Clin Endocrinol Metab 1998; 83: 370-373.
26. Chiumello G, Brambilla P, Guarneri MP, Russo G, Manzoni P, Sgaramella P. Precocious puberty and body composition: effects of GnRH analog treatment. J Pediatr Endocrinol Metab 2000; 13: 791-794.
27. Van der Sluis IM, Boot AM, Krenning EP, Drop SL, de Muinck Keizer-Schrama SM. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J Clin Endocrinol Metab 2002; 87: 506-512.
28. Lazar L, Kauli R, Pertzelan A, Phillip M. Gonadotropin-suppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height. J Clin Endocrinol Metab 2002; 87: 2090-2094.